AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Seqens North America Identifies Trends Affecting the Generic Drugs Sector in 2020

January 15, 2020 GMT

NEWBURYPORT, Mass.--(BUSINESS WIRE)--Jan 15, 2020--

SEQENS North America (formerly PCI Synthesis, Inc.), a pharmaceutical manufacturer of new chemical entities (NCEs), active pharmaceutical ingredients (APIs), and other specialty chemical products, issued its annual list of trends that will affect the emerging pharmaceutical and generic drug sectors, as well as Contract Development and Manufacturing Organizations (CDMOs), Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) in 2020.

“The industry will face more chaos in 2020 due to continued pressure to lower drug prices in the U.S., which means that Big Pharma as well as CDMOs need to continue to find ways to work smarter, more effectively to bring down costs that otherwise can exceed $2 billion before a drug is brought to market, based on estimates from Tufts University,” said Ed Price, president of Seqens NA. “We’re also seeing concerns about drug shortages and the need to stockpile some necessary drugs as well as a shortage of qualified chemists in 2020.”

Below are four trends that Seqens NA expects will impact the industry this year:

About SEQENS North America
Seqens North America (formerly PCI Synthesis) is a Pharmaceutical Development CDMO (Contract Development and Manufacturing Organization) based in Newburyport, Mass., a division of Seqens, an integrated global leader in pharmaceutical synthesis and specialty ingredients with 24 manufacturing sites and 3 R&D centers in Europe, North America and Asia.

Seqens North America is also a commercial manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products for the medical device industry. As a CDMO, Seqens North America provides emerging and mid-sized pharmaceutical companies access to the expertise needed to develop and manufacture complex small molecules. To learn more about SEQENS North America, its proprietary NCE development activities and process R&D capabilities please visit www.seqens.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20200115005267/en/

CONTACT: Linda Pendergast-Savage

Birnbach Communications

508-224-7905

lpendergastsavage@birnbachcom.com

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS

INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL OTHER MANUFACTURING GENERAL HEALTH HEALTH CHEMICALS/PLASTICS MANUFACTURING OTHER HEALTH

SOURCE: SEQENS North America

Copyright Business Wire 2020.

PUB: 01/15/2020 10:15 AM/DISC: 01/15/2020 10:16 AM

http://www.businesswire.com/news/home/20200115005267/en